Product Information
INVEGA TRINZA 410 MG/1.32 ML is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $3959.4621 per ML under NDC 50458060701. Its NADAC has been published 420 times since Jun 20, 2018.
FDA first approved this application on May 18, 2015.
Strength
410 mg/1.32mL
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458060701
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
PALIPERIDONE PALMITATEApproval Type
New Drug (NDA)
FDA Application
NDA207946FDA Approved
5/18/2015
On Market Since
5/19/2015
Pharmacological Classes
Price Statistics
The NADAC for INVEGA TRINZA 410 MG/1.32 ML has been published 420 times since Jun 20, 2018, and over the history we have for it it has risen 44.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3959.4621 per ML |
|---|---|
| All-time high | $3973.3790 (Jul 15, 2026) |
| All-time low | $2743.7703 (Jun 20, 2018) |
| 52-week high | $3973.3790 |
| 52-week low | $3875.0131 |
| Median price | $3435.1409 |
| Average price | $3430.4807 |
| Largest weekly change | +6.9% (Jan 16, 2019) |
| Weeks tracked | 420 |
| Tracking since | Jun 20, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the paliperidone palmitate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
paliperidone palmitate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INVEGA TRINZA 410 MG/1.32 ML?
The current National Average Drug Acquisition Cost (NADAC) for INVEGA TRINZA 410 MG/1.32 ML, manufactured by Janssen Pharmaceuticals Inc., is $3959.4621 per ML (NDC 50458060701), effective Sep 30, 2026.
How has the price of INVEGA TRINZA 410 MG/1.32 ML changed over time?
Over the history we have for it, the NADAC for INVEGA TRINZA 410 MG/1.32 ML has risen 44.3%. It has been tracked across 420 weekly CMS publications since Jun 20, 2018.
What are the highest and lowest recorded NADAC prices for INVEGA TRINZA 410 MG/1.32 ML?
Since Jun 20, 2018, the NADAC for INVEGA TRINZA 410 MG/1.32 ML has ranged from a low of $2743.7703 (Jun 20, 2018) to a high of $3973.3790 (Jul 15, 2026), with a median of $3435.1409 per ML.
Are there cheaper alternatives to INVEGA TRINZA 410 MG/1.32 ML?
No other NADAC-published product currently shares the active ingredient and strength of INVEGA TRINZA 410 MG/1.32 ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures INVEGA TRINZA 410 MG/1.32 ML?
INVEGA TRINZA 410 MG/1.32 ML (NDC 50458060701) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.